Serum C-telopeptide collagen crosslinks and plasma soluble VEGFR2 as pharmacodynamic biomarkers in a trial of sequentially administered sunitinib and cilengitide

BACKGROUND: Fit-for-purpose pharmacodynamic biomarkers could expedite development of combination anti-angiogenic regimens. Plasma sVEGFR2 concentrations ([sVEGFR2]) mark sunitinib effects on the systemic vasculature. We hypothesized that cilengitide would impair microvasculature recovery during suni...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Clin Cancer Res
Hoofdauteurs: O’Donnell, Peter H., Karovic, Sanja, Karrison, Theodore G., Janisch, Linda, Levine, Matthew R., Harris, Pamela J., Polite, Blase N., Cohen, Ezra E.W., Fleming, Gini F., Ratain, Mark J., Maitland, Michael L.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2015
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4677671/
https://ncbi.nlm.nih.gov/pubmed/26199386
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-0427
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items